Compare
Envista Holdings Corp vs Insulet Corp vs Globus Medical Inc vs West Pharmaceutical Services Inc
| Latest fiscal year | Envista Holdings Corp NVST | Insulet Corp PODD | Globus Medical Inc GMED | West Pharmaceutical Services Inc WST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.72B | $2.71B | $2.94B | $3.07B |
| Revenue growth (YoY) | +8.3% | +30.7% | +16.7% | +6.3% |
| Gross margin | 54.7% | 71.6% | 67.4% (computed) | 35.9% |
| Operating margin | 7.9% | 17.5% | 16.3% | 19.0% |
| Net margin | 1.7% | 9.1% | 18.3% | 16.1% |
| Net income | $47.00M | $247.10M | $537.87M | $493.70M |
| EPS (Diluted) | $0.28 | $3.48 | $3.92 | $6.79 |
| Operating cash flow | $275.70M | $569.30M | $753.45M | $754.80M |
| Free cash flow | $230.40M | $377.70M | $588.77M | $468.90M |
| Cash & equivalents | $1.21B | n/a | $526.16M | $791.30M |
| Total assets | $5.68B | $3.19B | $5.30B | $4.27B |
| Total liabilities | n/a | $1.68B | $729.51M | $1.09B |
| Shareholders' equity | $3.11B | $1.52B | $4.57B | $3.18B |
| Return on year-end equity | 1.5% | 16.3% | 11.8% | 15.5% |
| Shares outstanding | 163.80M | 70.39M | n/a | 72.00M |
Revenue, most recent five fiscal years
| Fiscal year | Envista Holdings Corp | Insulet Corp | Globus Medical Inc | West Pharmaceutical Services Inc |
|---|---|---|---|---|
| Latest | $2.72B Ended 2025-12-31 | $2.71B Ended 2025-12-31 | $2.94B Ended 2025-12-31 | $3.07B Ended 2025-12-31 |
| 1 year earlier | $2.51B Ended 2024-12-31 | $2.07B Ended 2024-12-31 | $2.52B Ended 2024-12-31 | $2.89B Ended 2024-12-31 |
| 2 years earlier | $2.57B Ended 2023-12-31 | $1.70B Ended 2023-12-31 | $1.57B Ended 2023-12-31 | $2.95B Ended 2023-12-31 |
| 3 years earlier | $2.57B Ended 2022-12-31 | $1.31B Ended 2022-12-31 | $1.02B Ended 2022-12-31 | $2.89B Ended 2022-12-31 |
| 4 years earlier | $2.51B Ended 2021-12-31 | $1.10B Ended 2021-12-31 | $958.10M Ended 2021-12-31 | $2.83B Ended 2021-12-31 |